8.25
+0.10
+(1.23%)
At close: 3:38:47 PM GMT+1
Breakdown
TTM
4/30/2024
4/30/2023
4/30/2022
4/30/2021
Total Revenue
--
--
5,271
--
--
Cost of Revenue
--
--
525
--
--
Gross Profit
--
--
4,746
--
--
Operating Expense
18,267
18,267
16,666
13,299
8,834
Operating Income
-18,267
-18,267
-11,920
-13,299
-8,834
Net Non Operating Interest Income Expense
-734
-734
-931
-1,773
-7,971
Pretax Income
-9,117
-9,117
-14,304
-6,272
-16,805
Tax Provision
-3,258
-3,258
-2,368
-1,703
-1,328
Net Income Common Stockholders
-5,859
-5,859
-11,936
-4,569
-15,477
Average Dilution Earnings
-8,853
-8,853
--
--
--
Diluted NI Available to Com Stockholders
-14,712
-14,712
-11,936
-4,569
-15,477
Basic EPS
-0.01
-0.01
-0.01
-0.00
-0.02
Diluted EPS
-0.01
-0.01
-0.01
-0.00
-0.02
Basic Average Shares
818,271.60
862,484.43
816,051.31
815,535.42
678,892.33
Diluted Average Shares
819,981.78
1,029,794.47
816,051.31
815,535.42
678,892.33
Total Operating Income as Reported
-18,267
-18,267
-11,920
-13,299
-8,834
Rent Expense Supplemental
123
--
--
--
--
Total Expenses
18,267
18,267
17,191
13,299
8,834
Net Income from Continuing & Discontinued Operation
-5,859
-5,859
-11,936
-4,569
-15,477
Normalized Income
-12,210.91
-12,210.91
-10,723.54
-10,979.59
-15,477
Interest Income
355
355
284
4
3
Interest Expense
1,089
1,089
1,215
1,777
1,651
Net Interest Income
-734
-734
-931
-1,773
-7,971
EBIT
-8,028
-8,028
-13,089
-4,495
-15,154
EBITDA
-7,062
-7,062
-12,187
-3,755
-14,905
Reconciled Cost of Revenue
--
--
525
--
--
Reconciled Depreciation
966
966
902
740
249
Net Income from Continuing Operation Net Minority Interest
-5,859
-5,859
-11,936
-4,569
-15,477
Total Unusual Items Excluding Goodwill
9,884
9,884
-1,453
8,800
--
Total Unusual Items
9,884
9,884
-1,453
8,800
--
Normalized EBITDA
-16,946
-16,946
-10,734
-12,555
-14,905
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
3,532.09
3,532.09
-240.54
2,389.41
--
4/30/2021 - 2/12/2010
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
TCF.L Theracryf Plc
0.2250
0.00%
ACUT AccuStem Sciences, Inc.
0.4509
-0.07%
SAR.L Sareum Holdings plc
17.50
0.00%
OXB.L Oxford Biomedica plc
279.00
+0.18%
IMM.L ImmuPharma plc
2.5700
+0.39%
TRX.L Tissue Regenix Group plc
37.50
-1.32%
POLB.L Poolbeg Pharma PLC
2.7000
0.00%
ABVX.PA ABIVAX Société Anonyme
4.9700
+3.54%
FUM.L Futura Medical plc
9.90
+1.02%
HNSA.ST Hansa Biopharma AB (publ)
21.88
-1.08%